NCT06427226 2026-04-17
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Tanta University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT05521984 2026-04-02
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT07235280 2026-02-19
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT04887935 2025-10-01
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT06491680 2025-09-22
Cardiotoxicity in Breast Cancer Patients
Helwan University
Phase 4 Recruiting
NCT05989347 2025-03-19
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Yale University
Phase 1 Recruiting
NCT06304857 2024-12-04
PROTECTAA
4th Military Clinical Hospital with Polyclinic, Poland
Phase 3 Recruiting
NCT06711185 2024-12-02
DAPA-MYOCANCER
University of Campinas, Brazil
Phase 3 Recruiting
NCT06576375 2024-10-22
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
Future University in Egypt
Phase 3 Recruiting